AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03486236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZ
Description: TEZ was administered as part of a fixed-dose combination (FDC) tablet (TEZ/IVA)
Study NCT00954655 — intervention group
Intervention type: GENETIC
Intervention: mutation analysis
Study NCT00954655 — intervention group
Intervention type: GENETIC
Intervention: polymorphism analysis
Study NCT00954655 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study NCT02342951 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lung clearance index determination
Description: Lung clearance index determination
Study NCT04450875 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental group (with diet)
Description: Two nutritionists performed both diet instruction and 24-hour reminder monitoring monthly. At the end of the three-month follow-up, the 24-hour reminder data such as food consumed, daily rations, and the monthly average of milligrams of consumed methionine contained in the food, were recorded in a database for subsequent analysis.
Study NCT00373087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: entacapone
Description: entacapone
Study NCT00373087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: l dopa versus placebo
Description: l dopa versus placebo
Study NCT01220063 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation
Description: 10 Gy for 4 times (total 40 Gy)
Study NCT01220063 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan
Description: 40 mg/m² : Day 1 and day 8
Study NCT03486236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: IVA was administered as part of a FDC tablet (TEZ/IVA) and as a mono tablet
Study NCT03486236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebos
Description: Placebos matched to VX-440, TEZ, and IVA.
Study NCT01770184 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Program (CDSMP)
Study NCT02574221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: stannous fluoride toothpaste
Description: 0.454% stannous fluoride toothpaste
Study NCT02574221 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: cavity protection toothpaste
Description: 0.243% sodium fluoride toothpaste
Study NCT02677779 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CO2 laser
Description: Single session of CO2 laser debridement
Study NCT02677779 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional surgery
Description: Single session of traditional debridement
Study NCT01479725 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HBOT
Description: HBOT
Study NCT03818815 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: OP0201
Description: OP0201 20mg per day in two divided doses for 10 days
Study NCT03818815 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 0mg per day in two divided doses for 10 days
Study NCT03818815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-clavulanate
Description: Oral Amoxicillin-clavulanate in two divided doses for 10 days
Study NCT03818815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amoxicillin-clavulanate
Description: Oral Amoxicillin-clavulanate in two divided doses for 10 days
Study NCT00262405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zileuton
Study NCT00262405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azathioprine/prednisone
Study NCT00756002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 4 mg, tablets, orally, once daily for up to 5 weeks.
Study NCT00756002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ramelteon placebo-matching tablets, orally, once daily for up to 5 weeks.
Study NCT01442584 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ovarian transplantation
Description: ovarian transplantation
Study NCT03405103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Striving
Study NCT03405103 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Boning-Up
Study NCT03405103 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Personal Choice
Study NCT03717922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Intensity Focused Ultrasound Pulsation to Amygdala
Description: Low intensity focused ultrasound pulsation will be administered to the amygdala in 10 sonications at 650kHz, ispta 720mW/cm, pulse repetition frequency 10Hz, duty cycle 5% duration 30s, with 30s spacing between sonications. Prior to receiving LIFUP sonication, the LIFUP transducer will be aimed at the amygdala and gently strapped in place to their head. Participants will then return to the scanner where a T1 image will verify the position of the LIFUP transducer and allow for estimation of the spatial location of the sonication beam focus. If needed, adjustments to transducer placement will be made to ensure that the beam focus is correctly aimed; an additional T1 will be collected after adjustment. Once correct placement of the transducer has been confirmed, LIFUP will be administered.
Study NCT03717922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Intensity Focused Ultrasound Pulsation to Entorhinal Cortex
Description: Low intensity focused ultrasound pulsation will be administered to the entorhinal cortex in 10 sonications at 650kHz, ispta 720mW/cm, pulse repetition frequency 100Hz, duty cycle 5% duration 30s, with 30s spacing between sonications. Prior to receiving LIFUP sonication, the LIFUP transducer will be aimed at the entorhinal cortex and gently strapped in place to their head. Participants will then return to the scanner where a T1 image will verify the position of the LIFUP transducer and allow for estimation of the spatial location of the sonication beam focus. If needed, adjustments to transducer placement will be made to ensure that the beam focus is correctly aimed; an additional T1 will be collected after adjustment. Once correct placement of the transducer has been confirmed, LIFUP will be administered.
Study NCT01029561 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Treatment with Continuous Positive Airway Pressure
Study NCT01029561 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Conventional diet treatment that undergo patients in the Bariatric Surgery Program
Study NCT02214589 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral glucose, facilitated tucking, NNS
Study NCT02214589 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral glucose and NNS
Study NCT02214589 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facilitated tucking and NNS
Study NCT03623750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR-TK Inhibitor
Description: Patients will commence daily oral therapy with the EGFR TKI afatinib as soon as possible, preferably on the same day as low dose cyclophosphamide. Afatinib will be prescribed according to the Summary of Product Characteristics (SmPC) of the product, and will continue in nominal 21-day cycles for as long as clinically indicated.
Study NCT03623750 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EGF-PTI
Description: The first day of dosing with EGF-PTI will be designated Day 1. Immunisation with EGF-PTI will commence 3 days after low dose cyclophosphamide and commencement of EGFR TKI, and will be repeated on Day 14, Day 28, Day 43, and Day 92. After the 5~th vaccination, patients will enter a maintenance phase during which reduced dose vaccinations will be performed every 2 or 3 months in conjunction with the interval between detailed check-up of the patient. As this interval can vary between patients, the interval for maintenance vaccination can also vary between 2 and 3 months.
Study NCT03623750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Eligible patients will receive a single pre-treatment of low dose of intravenous cyclophosphamide 200 mg/m2 (Day -3).
Study NCT00298532 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Advanced Life Support
Study NCT04589767 — intervention group
Intervention type: BEHAVIORAL
Intervention: CAPD scale
Description: Two nurses will apply CAPD scale. One nurse will repeat the CAPD evaluation two minutes later
Study NCT02962557 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NM3, Phillips Medical, Wallingford CT: verbal prompts to breathe with an optional shoulder shake
Description: The device used is the NM3 by Phillips Medical, Wallingford CT. The prompting for breaths will include a recorded voice played at 100 decibels played by a speaker placed within 4 feet of the patient's head. If successful breath response is monitored by the patient monitors but no additional subsequent breaths occur within 20 seconds, the verbal prompt will be repeated for the patient to breathe. If the verbal prompting does not result in a breath detected by the patient monitors, the verbal prompt will be repeated within 20 seconds, optionally accompanied by a shoulder shake from the shoulder massager.
Study NCT01888588 — intervention group
Intervention type: DRUG
Intervention: Risk of symptomatic peptic ulcer
Description: Current use of drugs (ASA; NSAIDs, SSRI,PPI, H2RA) versus non-use
Study NCT02732730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: 400 women who accept to initiate PrEP
Study NCT01651598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BI 144807
Description: multiple dose (bid)
Study NCT01651598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 144807
Description: multiple dose (bid, low to high dose)
Study NCT01163656 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Miller Laryngoscope
Description: Device is used to facilitate tracheal intubation.
Study NCT01163656 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope Cobalt Video Laryngoscopes
Description: The laryngoscope design with the integration of video technology into the laryngoscope blade.
Study NCT03632447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leva
Description: Subjects randomized to Leva will use a vaginal probe containing motion-based sensors to direct the performance of pelvic muscle exercises.
Study NCT03632447 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFDx
Description: All subjects (in both study arms) will be evaluated using a vaginally placed device that will evaluate pelvic floor motion to document change in pelvic floor muscle function resulting from pelvic floor muscle exercises.
Study NCT01085253 — intervention group
Intervention type: OTHER
Intervention: 3T and 7T MR imaging
Description: all patients and controls will be explored using a 3T and 7T MR imaging
Study NCT02020720 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo image-guided biopsy
Study NCT02020720 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo 18F-DOPA-PET/CT
Study NCT02020720 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diffusion Weighted Imaging
Description: Undergo DTI
Study NCT02020720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 Fluorodopa
Description: Undergo 18F-DOPA-PET/CT
Study NCT02020720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02020720 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perfusion Magnetic Resonance Imaging
Description: Undergo pMRI
Study NCT02020720 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo 18F-DOPA-PET/CT
Study NCT02020720 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo stereotactic craniotomy
Study NCT03699319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI 613
Description: Standard Dose Cohort: CPI-613, 500 mg/m2, IV infusion at a rate of 4 mL/min via a central venous port on days 1 and 3 of each cycle, every 2 weeks.~Dose Escalation Cohort: CPI-613, 750-1000 mg/m2 IV infusion at a rate of 3 mL/min via a central venous port on days 1 and 3 of each cycle, every 2 weeks.~Intended treatment protocol is 12 cycles (2 weeks each) or 6 months
Study NCT03699319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered at 65 mg/m2 given as a 2-hr IV~Part of SOC mFOLFRINOX treatment combination of Oxaliplatin, Irniotecan, 5-flurouracil, and vitamin derivative (Folinic acid)
Study NCT03699319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Administered at 140 mg/m2 given as a 90-min IV infusion) via a Y-connector~Part of SOC mFOLFRINOX treatment combination of Oxaliplatin, Irniotecan, 5-flurouracil, and vitamin derivative (Folinic acid)
Study NCT03699319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-flurouracil
Description: Administered at 400 mg/m2 as bolus followed by a 46-hr infusion at 2400 mg/m2, starting immediately after completion of folinic acid and irinotecan~Part of SOC mFOLFRINOX treatment combination of Oxaliplatin, Irniotecan, 5-flurouracil, and vitamin derivative (Folinic acid)
Study NCT03699319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid
Description: Administered at 400 mg/m2 given as a 90-min infusion immediately after oxaliplatin~Part of SOC mFOLFRINOX treatment combination of Oxaliplatin, Irniotecan, 5-flurouracil, and vitamin derivative (Folinic acid)
Study NCT02182245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Study NCT02182245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT02182245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT02291250 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sugar matched water with polycal OGTT
Description: Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups
Study NCT04053296 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: We follow up the results of patients.
Study NCT03163342 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Licensed seasonal influenza vaccine
Description: 20 healthy subjects will be enrolled and receive a single dose of licensed seasonal influenza vaccine
Study NCT02185469 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumatic retinopexy
Description: First, a 5/8-in 25-gauge needle will be used to perform an anterior chamber paracentesis, aiming to withdraw a minimum of 0.3 ml of aqueous fluid form the anterior chamber. Then, sulfur hexafluoride (SF6) will be injected in the vitreous cavity. The total volume of gas injected will exceed by 0.3 ml the amount of fluid withdrawn by the anterior chamber paracentesis (ex: 0.6 ml of SF6 would be injected after having withdrawn 0.3 ml). The laser retinopexy will be performed 48 hours later with laser.
Study NCT03632447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFDx
Description: All subjects (in both study arms) will be evaluated using a vaginally placed device that will evaluate pelvic floor motion to document change in pelvic floor muscle function resulting from pelvic floor muscle exercises.
Study NCT02184260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizole
Study NCT02184260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01932177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus and sorafenib
Description: Everolimus will be given alone during a 2 week run-in period before starting sorafenib. Subsequently sorafenib will be administered twice a day while everolimus will be given once a day continuously.
Study NCT01932177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus and sorafenib
Description: Everolimus will be given alone during a 2 week run-in period before starting sorafenib. Subsequently sorafenib will be administered twice a day while everolimus will be given once a day continuously.
Study NCT01932177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus and sorafenib
Description: Sorafenib will be given alone during a 2 week run-in period before starting everolimus. Subsequently sorafenib will be administered twice a day while everolimus will be given once a day continuously.
Study NCT01932177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus and sorafenib
Description: Sorafenib will be given alone during a 2 week run-in period before starting everolimus. Subsequently sorafenib will be administered twice a day while everolimus will be given once a day continuously.
Study NCT01932177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus and sorafenib
Description: Bid sorafenib will be given every other week alternating with 1 week qd everolimus. Doses will be escalated.
Study NCT01932177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus and sorafenib
Description: Bid sorafenib will be given every other week alternating with 1 week qd everolimus. Doses will be escalated.
Study NCT01932177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus and sorafenib
Description: Sorafenib will be given twice a day for 3 days-on 4 days-off while everolimus will be administered continuously on a daily basis. Doses will be escalated.
Study NCT02185469 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vitrectomy
Description: Under certain circumstances, pneumatic retinopexy can't be considered as a primary treatment for rhegmatogenous retinal detachment. In these cases, the patient will be booked for urgent 25 G vitrectomy with intraoperative laser retinopexy and gas injection to treat retinal detachment
Study NCT02185469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulfur hexafluoride (SF6)
Study NCT01932177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus and sorafenib
Description: Sorafenib will be given twice a day for 3 days-on 4 days-off while everolimus will be administered continuously on a daily basis. Doses will be escalated.
Study NCT02221921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MicroPort's Transcatheter Aortic Valve and Delivery System
Study NCT02255292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabidiol (CBD)
Description: Patients with confirmed solid cancer, after progression of all the available standard therapy or unfit to standard therapy according to oncologist's view, measurable disease as determined by RECIST using CT, life expectancy of at least 6 months, Eastern Cooperative Oncology Group (ECOG) performance status \< or = 2 and aged 18 years old and more will be included in the current study
Study NCT02185469 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 5/8-in 25-gauge needle
Study NCT03755050 — intervention group
Intervention type: OTHER
Intervention: general and specific data
Description: General and specific data collected
Study NCT00938795 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Uncertainty Management Intervention
Description: Six 30-minute telephone calls with a nurse to discuss emotional and physical aspects of liver disease and awaiting liver transplant
Study NCT00938795 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Comparison Conditions for Liver Transplant
Description: Six 30-minute telephone calls that provide structured education about liver disease.
Study NCT03392454 — intervention group
Intervention type: PROCEDURE
Intervention: T+LRTI
Description: T+LRTI is the most commonly used procedure, it removes the entire trapezium
Study NCT03392454 — intervention group
Intervention type: PROCEDURE
Intervention: PT+TI
Description: The PT+TI is less invasive than the T+LRTI as only part of the trapezium is removed
Study NCT00272519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Skills Intervention
Description: Developed to promote life skills among young adolescents perinatally infected with HIV
Study NCT00407030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA (Xeomin) (240 Units)
Description: incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (240 Units)
Study NCT00407030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA (Xeomin) (120 Units)
Description: incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (120 Units)
Study NCT00407030 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00235313 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dose adjustment of nicotine replacement therapies
Description: Dose adjustment of nicotine replacement therapies